{"entity":{"id":"nct07197827","kind":"trial","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","summary":"A Study of YL242 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07197827 by MediLink Therapeutics (Suzhou) Co., Ltd., with 424 participants planned, started 2025-09-22 and due to reach its primary completion in 2028-09. Interventions recorded: YL242, YL242; Pembrolizumab, YL242; 5-FU; LV and YL242; Pembrolizumab; 5-FU.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07197827","url":"https://clinicaltrials.gov/study/NCT07197827"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07197827","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors.","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","enrolled":424,"outcomes":[]},"route":"/trials/nct07197827/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}